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Highlights: 
 Blood transfusion is a very common therapeutic intervention in hospitalized patients 
 Enhanced understanding is required of the efficacy of transfused RBCs in vivo. 
 Evaluating efficacy requires non-invasive measures of tissue perfusion and oxygenation 
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Introduction 
Because blood transfusion is one of the most common therapeutic interventions in hospitalized 
patients, much recent research has focused on improving the storage quality in vitro of donor 
red blood cells (RBCs) that are then used for transfusion. However, there is a significant need 
for enhancing our understanding of the efficacy of the transfused RBCs in vivo. To this end, the 
NIH sponsored a one-and-a-half-day workshop that brought together experts in multiple 
disciplines relevant to tissue oxygenation (e.g., transfusion medicine, critical care medicine, 
cardiology, neurology, neonatology and pediatrics, bioengineering, biochemistry, and imaging). 
These individuals presented their latest findings, discussed key challenges, and aimed to 
construct recommendations for facilitating development of new technologies and/or biomarker 
panels to assess tissue oxygenation in a minimally-invasive to non-invasive fashion, before and 
after RBC transfusion.  
 
The workshop was structured into four sessions: (1) Global Perspective; (2) Organ Systems; (3) 
Neonatology; and (4) Emerging Technologies. The first day provided an overview of current 
approaches in the clinical setting, both from a global perspective, including the use of 
metabolomics for studying RBCs and tissue perfusion, and from a more focused perspective, 
including tissue oxygenation assessments in neonates and in specific adult organ systems. The 
second day focused on emerging technologies, which could be applied pre- and post-RBC 
transfusion, to assess tissue oxygenation in minimally-invasive or non-invasive ways. Each day 
concluded with an open-microphone discussion among the speakers and workshop participants. 
The workshop presentations and ensuing interdisciplinary discussions highlighted the potential 
of technologies to combine global “omics” signatures with additional measures (e.g., thenar 
eminence measurements or various imaging methods) to predict which patients could 
potentially benefit from a RBC transfusion and whether the ensuing RBC transfusion was 
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effective. The discussions highlighted the need for collaborations across the various disciplines 
represented at the meeting to leverage existing technologies and to develop novel approaches 
for assessing RBC transfusion efficacy in various clinical settings.  
 
Although the Workshop took place in April, 2018, the concepts described and the ensuing 
discussions were, perhaps, even more relevant in April, 2020, at the time of writing this 
manuscript, during the explosive growth of the COVID-19 pandemic in the United States. Thus, 
issues relating to maintaining and improving tissue oxygenation and perfusion are especially 
pertinent because of the extensive pulmonary damage resulting from SARS-CoV-2 infection [1], 
compromises in perfusion caused by thrombotic-embolic phenomena [2], and damage to 
circulating RBCs, potentially compromising their oxygen-carrying capacity [3]. The severe end 
organ effects of SARS-CoV-2 infection mandate even more urgency for improving our 
understanding of tissue perfusion and oxygenation, improve methods for measuring and 
monitoring them, and develop novel ways of enhancing them.  
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General Session I 
 
Keynote: Framing the Challenge: Quantifying Impact of Anemia/Transfusion upon O2 
Delivery Homeostasis 
Allan Doctor, M.D., University of Maryland 
 
Transfusion decision-making should maintain hemoglobin levels above thresholds that limit O2 
delivery or that impose problematic or unsustainable stress on compensatory physiology. 
Historically, near-normal values were presumed necessary to achieve this goal, particularly 
during stress imposed by illness. We now better appreciate (1) the role of RBCs in O2 delivery 
homeostasis, beyond simple O2 transport [4], (2) the extent of physiologic compensation for 
anemia (tolerance), (3) the damage to RBCs during storage [5], and (4) the impacts of non-
infectious serious hazards of transfusion. As such, conservative transfusion approaches are 
emerging, based on non-inferiority trials of permissive anemia (e.g. restrictive hemoglobin-
based thresholds) [6]. However, we lack a decision-making structure that identifies specific 
individuals for whom permissive anemia is unsafe (or, conversely specific individuals meeting 
transfusion “triggers” for whom transfusion is unnecessary) and guides transfusion timing and 
amount, based on outcome-linked, O2 delivery-based targets. Significant knowledge gaps 
contribute to this lack, because we cannot reliably determine: (1) the onset and severity of 
inadequate O2 delivery, or “pre-failure” physiology that indicates impending inadequate O2 
delivery that would be prevented by transfusion, (2) the degree to which anemia contributes to 
inadequate O2 delivery in patients with complex pathologies, (3) the likelihood that inadequate 
O2 delivery will respond to transfusion, (4) the context-specific assessment of transfusion 
risk/benefit, and (5) the appropriate amount to transfuse, if initiated. Moreover, patients rarely 
have isolated anemia, and various co-morbidities generate unique physiology requiring 
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individualized approaches; examples affecting O2 delivery include: low cardiac output (i.e., heart 
failure), hypoxia (e.g., cyanotic pulmonary or heart disease), vasculopathy (e.g., stroke, shock), 
or altered metabolism (e.g., hypothermia, burns, sepsis).  
 
Although RBC transfusion increases hemoglobin levels and blood O2 content, it does not 
necessarily increase tissue O2 delivery or relieve compensatory physiology, unless blood O2 
content is rate-limiting for transferring O2 from lung to tissue. Currently, transfusion decisions 
aim to maintain RBC mass well above a threshold that may critically limit tissue O2 delivery. 
Although traditional thresholds are currently being re-evaluated, a comprehensive paradigm 
shift is emerging that re-considers the “hemoglobin trigger” strategy itself. Clearly, it is not 
feasible to define specific hemoglobin goals that account for all the complex developmental, 
disease-related, and stress-specific situations that complicate anemia. Ideally, transfusion 
decisions should be based on individual, context-specific considerations of the degree to which 
anemia contributes to tissue O2 delivery constraints and/or reserves. This may involve 
“physiologic triggers” to improve perfusion sufficiency or reserve, rather than to maintain a 
specific hemoglobin level, irrespective of context [7].  
 
To identify the best means to define and evaluate approaches to transfusion decision-making 
with patient-specific physiologic targets, several knowledge gaps must be addressed; as 
examples, there are no data supporting a physiologic goal-directed strategy, no consensus on 
what goals should be targeted, and no consensus on what thresholds are appropriate for these 
goals. Therefore, we must improve the current means to assess the functionality of the 
circulating RBC mass and its relationship to tissue O2 delivery, an area of investigation ripe for 
translation [8]. Some potential focus areas include: 
a. Studies examining physiologic tolerance of anemia in the critically ill  
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b. Studies exploring accuracy, precision, and reliability of novel approaches to quantify 
and monitor O2 consumption and delivery 
i. Methods might include: bedside VO2 measurement, dynamic near infrared 
spectroscopy (NIRS) measurements, using nanoparticles that report real-time 
measurement of tissue O2 levels or the abundance of biochemical markers of 
perfusion sufficiency (e.g., pH, lactate, reactive oxygen species, cytochrome redox 
state). 
ii. Integrated approaches using real-time risk analytic engines that evaluate multiple 
data streams (e.g., from monitors, laboratory results, and the electronic health 
record), 
c. Studies exploring accuracy, precision, and reliability of novel approaches to quantify 
and monitor “erythron” status (e.g., circulating blood volume; RBC mass, production, 
and clearance; RBC performance (e.g., O2 affinity, deformability, adhesion, vasoactivity))  
d. Studies evaluating transfusion decision making during critical illness (e.g., Bayesian 
modeling, application of systems dynamics, development of computerized decision 
support). These should address the issue of sequencing; for example, with the complex 
pathology commonly encountered in intensive care units, what is optimal timing of RBC 
transfusion in a therapeutic sequence that targets impaired O2 delivery (e.g., when 
anemia complicates impaired respiratory and cardiovascular performance or contributes 
to organ-specific threats)? 
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Global Perspective Session I (Session Chair: Steven Spitalnik, M.D., 
Columbia University) 
 
Overview of measuring tissue oxygenation in the clinical setting 
Walter “Sunny” Dzik, M.D., Harvard University 
 
The basic concept of oxygen extraction as a measure of compensation for decreased oxygen 
delivery was reviewed. This highlighted the shortcomings of measuring oxygen extraction ratios 
as a reliable guide for adequate tissue oxygenation in settings of variable oxygen delivery (i.e., 
microvascular dysoxia) and variable tissue oxygen demands. Oxygen extraction measurement 
is fundamental to several technologies, such as NIRS and blood oxygen level dependent 
(BOLD) imaging, and the reliance on extraction ratios represents a shortcoming of these 
techniques. In addition, hemoglobin is not the final molecule in the chain of oxygen delivery to 
tissues and additional attention should evaluate the role of myoglobin in transferring oxygen 
from hemoglobin to the mitochondria.  
 
Three methods for measuring tissue oxygenation were reviewed:  NIRS, BOLD, and 
assessment of hypoxia-inducible factor (HIF). In a meta-analysis of papers involving cardiac 
surgery [9], RBC transfusion decisions guided by NIRS measurements did not significantly 
improve rates of adverse end-organ clinical outcomes. However, NIRS monitoring did identify 
improved regional cerebral oxygenation following RBC transfusion in severely anemic children 
[10].  
 
Because most RBC transfusions for non-bleeding patients aim to increase the reserve of tissue 
oxygenation, measurements of “compensation to reduced oxygenation” may be useful 
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physiological triggers for RBC transfusion. In addition, some type of “stress test” that uncovers 
reduced oxygenation reserve may identify the patients most likely to benefit from RBC 
transfusion. BOLD imaging relies on detecting deoxy-hemoglobin, which has a faster T2 
relaxation time due to the paramagnetic properties of iron in deoxy-hemoglobin. Although BOLD 
imaging offers the advantage of deep tissue visualization of oxygen, its disadvantages include 
measuring hemoglobin saturation (rather than tissue oxygen content) and requiring a magnetic 
resonance imaging (MRI) instrument.  
 
Although HIF measurements are not yet clinically available to guide transfusion, assessing a 
tissue’s metabolic status with regard to adequate oxygenation would be significantly and 
importantly complement assessing the presence of oxygen itself. Multiple candidate molecules, 
including HIF, lactate-pyruvate, NAD/NADH, mitochondrial enzymes, and local CO2 production, 
might serve as biomarkers of locally inadequate tissue oxygenation. Ultimately, the ideal device 
would target deep tissues of interest (e.g., heart, brain, liver, gut, kidney), measure real-time 
oxygen reserve at the bedside (i.e., stress testing), and provide information on the quantity of 
oxygen present and the metabolic status of the relevant target tissue.   
 
Metabolomics for studying RBCs and tissue perfusion 
John Roback, M.D., Ph.D., Emory University School of Medicine 
  
Although many groups are developing novel devices or imaging modalities to identify hypoxic 
patients who could benefit from RBC transfusion, this talk focused on RBC and plasma 
biomarkers that could improve the safety and efficacy of transfusion therapy. 
 
Most published transfusion medicine metabolomics data aim to understand the metabolic 
changes that occur during RBC storage. However, one can also leverage the availability of RBC 
         
 
14 
 
units from known good-storing and poor-storing donors to identify metabolic pathways that differ 
between these two storage phenotypes with the goal of identifying metabolic biomarkers that 
predict RBC storage behavior. Although the data set of pedigreed donors with these divergent 
phenotypes in one study was small (i.e., 6 good-storing and 4 poor-storing donors), the data 
were robust and supplied clues to the biology underlying these storage phenotypes. For 
example, recent findings [11] demonstrated that, although RBC donor units were largely 
indistinguishable in their post-transfusion effects on the recipient if stored between 7-35 days 
prior to transfusion, dramatic differences were seen at 35-42 days of storage, suggesting that 
there is an inflection point in storage after Day 35, and that RBCs transfused at Day 42 of 
storage may have entered the steeply descending part of the quality curve. However, RBCs 
from some poor-storing donors may experience this inflection point earlier in storage, which 
could be a subject for future research. 
 
Much less published information exists regarding metabolic biomarkers that could improve on 
the currently used clinical laboratory tests (e.g., blood lactate levels [10]), along with clinical 
features, to identify patients who would benefit from transfusion. Although one informative paper 
[12] used metabolomics to identify blood biomarkers that increased or decreased after 
experimental hemorrhagic shock in rats, much more needs to be done, including determining 
whether transfusions can abrogate the observed metabolic changes.   
 
Overview of RBC biology in the transfusion setting 
Narla Mohandas, Ph.D., New York Blood Center 
 
Much research has focused on the RBC “storage lesion.” The described changes include a 
rapid early decrease in RBC 2,3-diphosphoglycerate levels followed by time dependent 
decreases in cellular ATP and increases in plasma hemoglobin levels and numbers of 
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microparticles, starting at >4 weeks during storage. Although these changes are highly 
reproducible, their impact on the function of the transfused RBCs in vivo is not clear. In large 
part, this is because many of these studies are correlative and not mechanistic.  
 
In addition, the cellular deformability of stored RBCs is normal until they become sphero-
echinocytes and spherocytes due to the progressive loss of surface area. These changes occur 
later in storage (i.e., >4 weeks). If the storage lesion is defined as decreased post-transfusion 
recovery of the donor RBCs, the reduced deformability of stored RBCs due to cell surface area 
loss and increased sphericity leading to splenic sequestration can account for decreases in 24-
hour post-transfusion recovery [13]. Nonetheless, how different extents of loss of deformability 
influence tissue oxygen delivery by the transfused RBCs still remaining in the circulation is 
unclear. 
 
Regarding future studies, a clearer definition of the storage lesion is needed that functionally 
relates to RBC life span and effective oxygen delivery. The biological variability between donors 
in RBC storage quality could also be important, but addressing this issue requires thoughtful 
and critically-validated study designs. In addition, biological changes in RBCs during storage 
have been well documented, but the physiological basis for their reduced survival post-
transfusion has not been critically validated. Finally, developing non-invasive or minimally 
invasive strategies for measuring stored RBC efficacy in delivering oxygen to various tissues in 
vivo is the most important issue in RBC transfusion research; although this is a challenging 
problem, integrated, multi-disciplinary approaches are likely to be successful.  
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Organ Systems Session II (Session Chair: Allan Doctor, M.D., 
University of Maryland) 
 
Tissue-integrating sensors for long-term, continuous monitoring of interstitial 
oxygenation: use in limb ischemia, trauma/resuscitation, respiratory function, and brain 
hypoxia 
Natalie Wisniewski, Ph.D., Profusa 
 
Currently available wearable/external monitoring tools have faltered in providing clinical-grade, 
real-time, biochemical data at the tissue level. Tissue-integrating sensor technology may enable 
wearables to live up to their promise of improving healthcare [14]. These novel biosensors are 
composed of tissue-like hydrogel scaffolds that reside permanently under the skin and use 
existing mobile networks to provide real-time continuous wireless biochemical data for remote or 
cellphone viewing. These soft, porous, oxygen sensing scaffolds, functionalized with 
luminescent chemistries, perform in vivo for more than 4 years. In this setting, tissue grows in 
and throughout the porous sensor scaffolds, but avoids a foreign body response, and enables 
long-term sensing. Oxygen levels (or other analytes that the sensors can detect) trigger 
concentration-dependent, reversible changes in optical properties. These optical changes occur 
in the NIR range and are readily detectable through the skin; thus, a NIR detector is placed at 
the skin surface without needing to insert a fiberoptic probe. After the initial scaffold insertion, 
measurements are collected non-invasively, allowing long-term longitudinal tracking of tissue 
hypoxia.   
 
The first such tissue-integrating sensor is approved for use in the European Union for 
continuous monitoring of tissue oxygen, and is currently seeking FDA approval. These sensors 
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have been used in multiple clinical applications, including critical limb ischemia, trauma models 
of hemorrhage and resuscitation, pilot hypoxia and other high-altitude applications, wound 
healing, tumor hypoxia, exercise physiology, sepsis, and stroke models. Sensors remain 
subcutaneously and cannot be felt or seen, except by a specialty wearable optical reader to 
visualize them and record their signals. This same tissue-integrating sensor platform is currently 
being adapted to measure lactate, glucose, carbon dioxide, and various ions and other 
molecules, with the goal of measuring a continuous “Chem-7” panel that is relayed automatically 
to a cellphone and the cloud; this would allow remote monitoring and applying artificial 
intelligence algorithms to guide health and treatment decision-making. Thus, this approach 
would also be applicable for real-time monitoring of tissue health related to blood transfusion 
outcomes. 
 
Oxygen imaging in tissue by phosphorescence quenching 
Sergei Vinogradov, Ph.D., University of Pennsylvania 
 
Phosphorescence quenching relies on exogenous phosphorescent (optical) probes to measure 
dissolved oxygen [15]. It is accurate and versatile with many current research applications, 
ranging from simple-to-implement peripheral oxygen measurements with fiber optic oximeters to 
high-resolution pO2 microscopy in the brain. Variants exist in which plastics or gels containing 
phosphorescent dyes are either implanted or laid over the target tissue to provide local 
oxygenation measurements; oxygen measurements of the skin can also be made, which 
potentially correlate with oxygenation of the underlying tissue. Indeed, phosphorescence was 
effective in assessing the efficacy of RBC transfusion [16]. Key advantages of phosphorescence 
include that it is exquisitely sensitive to oxygen, is calibration free (with properly designed 
soluble probes), and provides absolute pO2 measurements; in addition, such instrumentation 
can be compact and inexpensive. However, it has low resolution at a depth of several 
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centimeters (similar to NIRS). In addition, for imaging over larger areas, volumetric imaging 
probes must be dissolved in the interstitial fluid; thus, there is direct contact between the probes 
and the body, which is similar to other exogenous contrast agents. Nonetheless, a variant of the 
latter method avoids direct contact of probes with tissues through the use of microscopic oxygen 
chambers, with the probe solution mounted at the tips of thin optical fibers, which are inserted 
into the target tissue. 
 
Tissue oxygenation with novel oxygen carrier therapeutics: overcoming hypoxia in 
stroke, cardiac ischemia and brain tumors 
Natacha Le Moan, Ph.D., Omniox 
 
Oxygen supply and diffusion into tissue are necessary for organ function and survival. Tissue 
oxygenation is disturbed in pathological situations, including cancer, diabetes, trauma, sepsis, 
heart disease, wound healing, and stroke. Omniox, a California-based company focused on 
biotherapeutics that target hypoxia, is developing oxygen carriers to treat diseases in which 
hypoxia drives poor outcomes [17]. They use direct and indirect methods to evaluate the effect 
of oxygen carriers on tissue oxygenation in preclinical models of cancer and ischemia. Direct 
measurements of tissue oxygenation with optical or polarographic sensor probes are often 
invasive or minimally invasive, which limits continuous and repetitive measurements over long 
periods of time; thus, they only provide a snapshot of tissue pO2 in a fixed region. Indirect 
methods can measure a parameter related to oxygenation in a large tissue area, but do not 
directly quantify tissue pO2. These indirect methods often use endogenous and/or exogenous 
markers of tissue oxygen content that can be detected by ELISA, immunohistochemistry, flow 
cytometry, or imaging techniques. Each method has advantages and disadvantages in 
sensitivity, specificity, reproducibility, and clinical applications. Thus, there is an important need 
to develop new approaches to assess oxygen levels continuously and repetitively in tissue using 
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non-invasive or minimally invasive tools. These would be applicable in various clinical settings 
for diagnosing and managing hypoxic and ischemic disorders. 
 
Tissue oxygenation in the kidney: lessons from BOLD MRI 
Stephen C. Textor, M.D., Mayo Clinic 
 
Renal circulation is complex, reflecting its roles in blood filtration, solute reabsorption, and blood 
pressure regulation. Although the cortical region is over-perfused with oxygenated blood, 
deeper medullary segments normally receive less blood perfusion and consume oxygen as a 
function of energy-dependent solute transport [18]. Hence, some regions function normally at 
hypoxic levels, as reflected by near complete transition to deoxygenated hemoglobin on the 
steep segments of the hemoglobin saturation curve. BOLD MRI uses the paramagnetic 
properties of deoxyhemoglobin to characterize local tissue oxygenation non-invasively; in 
addition, it does not require exogenous contrast agents. Studies using oxygen-sensing probes 
confirm the magnitude of changes during various maneuvers, including vascular occlusion, 
ureteral obstruction, and inhibition of solute transport. Experimental studies with lysed RBCs 
and varying hematocrit confirm that magnetic relaxation kinetics are affected by proximity to cell 
membranes, depending in part on the magnetic field strength. Research applications require 
attention to (patho)physiologic determinants of oxygenation, including sodium balance, water 
intake, diuretics, antihypertensive medications, and hematocrit [19]. Multiple analytic strategies 
exist, ranging from regions-of-interest, fractional tissue oxygenation, and computer-generated 
concentric objects within coronal sections. Studies in experimental animals and human subjects 
under controlled conditions demonstrated changes in kidney oxygenation associated with 
vascular occlusive disease, contrast administration, revascularization, and angiogenic 
maneuvers using mitochondrial protection, mesenchymal stromal/stem cell infusion, and 
vascular endothelial growth factors. Taken together, BOLD MRI provides reproducible, non-
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invasive estimation of tissue oxygenation in vivo in vascular tissues, such as the kidney, in 
humans. 
 
Wearable, paintable, and conformal transcutaneous oxygenation sensors for real-time 
pO2 quantification and imaging 
Conor L. Evans, Ph.D., Massachusetts General Hospital  
 
A new set of pO2 imaging technologies were discussed for quantitative transcutaneous 
oxygenation measurements and their potential for sensing tissue oxygenation changes related 
to transfusion. The motivation for developing these oxygen sensors came from problems faced 
by wounded warriors and their caregivers, who required non-invasive, non-disruptive tools to 
visualize and quantify tissue pO2 during surgery and throughout recovery. Several technologies 
were developed to address this, from perfusion imaging tools to TcPO2 devices, but none were 
suitable. To address this, we initially developed a conformal, paintable, and sprayable material 
that changes color quantitatively in response to oxygen. This technology uses porphyrin 
molecules in which red emission is turned-off, or "quenched," by oxygen. By pairing these with 
green-emitting dyes, a wearable bandage material was created that changed from green, to 
yellow, to red with decreasing oxygenation. Precise visual readout of tissue oxygenation is 
measured by the material's green-to-red emission ratio using common imaging equipment, such 
as point-and-shoot and smartphone cameras. 
 
These wearable sensors were evaluated using various animal models, including porcine skin 
burn, skin graft, and skin inflammation models, and mouse non-compressible trunk injury 
models. To overcome the weak emission properties of commercial porphyrins, a new class of 
ultrabright, "clickable," porphyrin molecules were developed that are readily functionalized for 
oxygen sensing applications [20,21]. A paintable bandage formulation of these new sensors 
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was tested in a successful clinical trial of deep epigastric flap breast reconstruction surgery in 
post-mastectomy breast cancer paints. The rate change of tissue pO2 of this thin film oxygen 
sensor was found to correlate well with StO2 rate changes. 
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Neonatology Session III (Session Chair: Naomi Luban, M.D., 
Children's National Health System) 
 
Oxygen saturation targets in neonatal patients 
Waldemar A. Carlo, M.D., University of Alabama at Birmingham 
 
Many critically ill neonates need oxygen supplementation to survive and reduce their risk of 
serious morbidity. However, optimal tissue oxygenation in neonates has been elusive. Data 
before the recent oxygen saturation targeting trials suggested that oxygen toxicity in preterm 
infants may increase the risk for retinopathy of prematurity, bronchopulmonary dysplasia, 
cerebral palsy, and death. Several contemporary observational studies suggested that targeting 
a lower oxygen saturation may reduce death, retinopathy of prematurity, and bronchopulmonary 
dysplasia. These and other studies suggested that oxygen saturation targeting below 90% 
would safely improve outcomes.  
 
Multicenter randomized clinical trials were conducted to determine if lower oxygen saturation 
targets (i.e., 85-89%) would improve outcomes, as compared to higher oxygen saturations (91-
95%) in extremely preterm infants (24-27 weeks at birth). The first was the Surfactant, Positive 
Pressure, and Pulse Oximetry Trial (SUPPORT) [22], and other trials were similarly designed. 
Meta-analyses, including 4965 infants, indicated that targeting a higher oxygen saturation 
decreased mortality and necrotizing enterocolitis. Even though higher oxygen saturation 
targeting led to more retinopathy of prematurity, the rates of blindness were not affected [23].  
 
However, arterial oxygen saturation does not necessarily correlate well with tissue oxygenation. 
As such, NIRS is increasingly used as a non-invasive tool for continuously monitoring tissue 
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oxygenation and hemodynamics, particularly in the brain. In a multicenter randomized clinical 
trial of extremely preterm infants, targeting cerebral hemoglobin oxygen saturation in the 55-
85% range decreased the burden of hypoxia by ~70% with trends for reduced all-cause 
mortality and brain injury; the latter defined as intracranial hemorrhage, white matter 
abnormalities, ventricular dilation, and cerebral atrophy. 
 
Ultrasound imaging of the human placenta: A new approach to the diagnosis of fetal 
health 
Alfred Abuhamad, M.D., Eastern Virginia Medical School 
 
Abnormal placental development in early gestation is associated with various maternal and fetal 
adverse outcomes, including preeclampsia, preterm labor, and fetal growth restriction. In 
addition, altered placental structure in early gestation produces placental dysfunction later in 
pregnancy, manifested by maternal and fetal disease. Alterations in placental structure include 
changes in placental biometry, tissue density, calcium content, and vascular supply. 
Abnormalities in placenta shear wave elastography also correlate with placental dysfunction, 
especially in diseased states, such as preeclampsia.  
 
Ultrasound is the optimal imaging modality for placental evaluation in early gestation, because it 
is noninvasive, applied in real time, widely available, and relatively inexpensive. Furthermore, 
ultrasound is relatively safe during pregnancy because it does not involve ionizing radiation. 
Novel ultrasound tools, such as elastography, calcium contact, and microvascular assessment, 
can be applied in early gestation for noninvasively evaluating the human placenta. These 
ultrasound findings can be correlated with non-optimal pregnancy outcomes, collectively defined 
as delivery at <37 weeks gestation for any indication. Preliminary data suggest a correlation 
between alterations in placental vascular structure and function and complications later during 
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pregnancy. One main goal is to combine ultrasound findings and maternal biomarker 
measurements in early gestation to create a placental index that predicts pregnancy outcomes 
later in gestation [24]. 
 
Keynote: Controversies in red cell transfusion in preterm infants: Opportunity for tissue 
oxygenation monitoring 
Ravi Mangal Patel, M.D., M.Sc., Emory University School of Medicine 
 
Preterm infants routinely receive RBC transfusions to improve oxygen delivery. Hemoglobin 
thresholds, which do not necessarily reflect adequate tissue oxygenation, often guide these 
transfusions. Therefore, the effect of conservative versus liberal RBC transfusion thresholds 
may differ for individual patients based on clinical context (e.g., surgery, sepsis, degree of 
prematurity, postnatal age) and adequacy of oxygen delivery in relation to oxygen consumption. 
Determining tissue oxygenation adequacy and related effects of RBC transfusion and anemia 
are relevant for key clinical outcomes, such as neurodevelopmental impairment and necrotizing 
enterocolitis. In addition, few studies considered donor RBC and recipient factors in assessing 
the effects of transfusion on tissue oxygenation. NIRS enables continuous, non-invasive 
monitoring of regional tissue oxygenation, including mesenteric, renal, and brain tissues. It may 
be useful in guiding the need for, and response to, RBC transfusion in preterm infants [25]. 
However, NIRS use is limited by a paucity of studies evaluating its relationship to regional 
oxygen saturation measurements and relevant clinical outcomes. In addition, assessing 
important, but infrequent, outcomes requires large, costly, cohort studies with longitudinal 
measurements. Furthermore, methods for analyzing tissue oxygenation data that appropriately 
account for signal dropout, signal below or above detection limits, and variability in tissue 
oxygenation parameters, are not commonly used [26]. Study designs involving longitudinal 
measures across multiple RBC exposures could allow for understanding “within patient” 
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variation in transfusion responses that could be related to variations in donor characteristics 
(e.g., sex, age), product characteristics (e.g., storage age, irradiation), or time-varying recipient 
characteristics (e.g., anemia severity). Such studies could improve our understanding of optimal 
RBC product characteristics or identify patient factors that influence responses to transfusion 
and how these responses may relate to important clinical outcomes.  
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Emerging Technologies Session IV (Session Chair: Steven Spitalnik, 
M.D., Columbia University) 
 
Breezing: A non-invasive device to measure overall metabolism 
Erica Forzani, Ph.D., Arizona State University 
 
Calorimeters can measure oxygen consumption rate (VO2) and carbon dioxide production rate 
(VCO2) using the indirect calorimetry method. This uses the gas exchange rate of oxygen and 
carbon dioxide to assess the energy produced by the individual performing the test at rest, 
known as Resting Energy Expenditure (REE) or Resting Metabolic Rate [27]. 
 
A novel indirect calorimeter device uses a single sensor chip allowing detection of both gases, 
which previously required electrochemical and infrared sensors. This BreezingTM sensing 
technology was validated against the “gold standard” method (i.e., the Douglas Bag) and 
demonstrated near 100% accuracy. 
 
Measurements are typically performed under resting conditions in a quiet environment, and 
assessing REE enables one to determine the nutritional needs for patient interventions related 
to weight management [28]. In addition, REE and the parameters associated with detecting 
VCO2 and VO2, such as exhalation rate (L/min), breathing frequency (breath/min), and end-tidal 
volume (mL), also indicate respiratory state and are useful for diagnosing pulmonary disease. 
Furthermore, indirect calorimetry can be used before and after exercise, dialysis, and meal 
supplements to evaluate the impact of these interventions on metabolic function. This approach 
could also be potentially useful for evaluating the physiological effects of RBC transfusions on 
overall metabolic function. 
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Role of NIRS to guide medical care and assess transfusion efficacy 
Elliott Bennett-Guerrero, M.D., Stony Brook University School of Medicine  
 
NIRS, introduced in 1977 and commercially available for ~20 years,  uses near infrared light 
(~700-900 nm) to detect the weighted average of hemoglobin saturation in arterial and venous 
blood in a small region under the sensor. This contrasts with pulse oximetry, which solely 
measures arterial oxygen saturation and venous oxygen saturation (i.e., SvO2 of pulmonary 
artery or “mixed venous” blood).  Most clinical applications of NIRS in adults focus on cerebral 
and peripheral tissue monitoring of “tissue oxygenation” in surgical, intensive care, and other 
high risk hospitalized patients. Common sites for peripheral measurements, with or without a 
vascular occlusion test, are the hand (i.e., the thenar eminence), forearm, and calf muscles. 
 
NIRS has several possible clinical roles and could potentially aid in testing RBC transfusion 
“quality” [29]. For example, cerebral NIRS can detect unilateral cerebral ischemia in cardiac and 
vascular surgery, where rapid detection and correction of flow imbalances due to surgical 
manipulation can be lifesaving. NIRS may also have a role in assessing oxygenation/perfusion 
of flaps after reconstructive plastic surgery. Chronic non-healing wounds heal better if 
oxygenation/perfusion can be optimized; therefore, NIRS measurements could potentially help 
in that setting. Several studies emphasized the potential for NIRS as an early warning indicator 
of impending decompensation from bleeding (e.g., in surgery and trauma). In addition, NIRS 
might help optimize global oxygen delivery in critically ill patients. Finally, there is interest in 
using NIRS to do “spot checks” (i.e., surveillance) in lower risk acute care patients who might 
have overt tissue hypoperfusion despite adequate arterial oxygen saturation.    
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In several studies, NIRS documented increased tissue oxygenation after RBC transfusion. 
However, increases in tissue oxygenation are usually subtle in patients who are not suffering 
from a critical level of anemia. Therefore, it is not clear what role NIRS should have in guiding 
whether a transfusion should be administered or in determining the efficacy of that transfusion. 
It is challenging to find patients with profound tissue hypoxia/anemia (e.g., a hemoglobin of ~3 
g/dL), where transfusion of multiple units of RBCs would dramatically change tissue 
oxygenation [10]. Nonetheless, inducing transient global hypoxia in healthy volunteers is 
possible; this was shown to be safe and, as such, NIRS could potentially be used in this context 
to assess RBC quality rigorously. 
 
Multiscale photoacoustic tomography of tissue oxygen  
Lei Li, Ph.D., California Institute of Technology, presenting on behalf of Lihong V. Wang, Ph.D.  
 
The life sciences and modern medicine can benefit from imaging technologies that bridge 
microscopic insights to macroscopic observations. Photoacoustic tomography (PAT) provides 
multiscale imaging over a range of spatial scales, including organelles, cells, tissues, whole 
bodies of small animals, and human organs [30].  
 
PAT is a hybrid imaging technique that combines optical and acoustic energy via the 
photoacoustic effect, a natural phenomenon that converts absorbed photons into acoustic 
waves. PAT inherits the advantages of both optical imaging and ultrasound imaging. PAT 
directly detects acoustic waves induced by the excitation photons, regardless of whether they 
are ballistic photons or scattered/diffused photons; thus, PAT achieves far greater penetration 
than optical microscopy. More importantly, acoustic waves are much less scattered inside 
biological tissues (i.e., ~3 orders of magnitude weaker than optical scattering on a per unit path 
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length basis); therefore, PAT provides much higher spatial resolution in deep tissue (i.e., from 1 
mm up to several centimeters) than pure optical imaging technology.  
 
PAT is sensitive to optical absorption and reveals anatomical, functional, metabolic, histological, 
and molecular information about biological tissues at high imaging speed. Taking advantage of 
the absorption spectral signatures of oxyhemoglobin and deoxyhemoglobin, PAT can map 
detailed blood oxygen saturation in mouse brains, mouse internal organs, and human finger 
cuticles [31]. 
 
Label-free functional imaging of single RBCs in vivo has the potential to uncover the 
fundamental mechanism of oxygen metabolism in cells. Photoacoustic microscopy (PAM) can 
non-invasively image oxygen delivery from single flowing RBCs in vivo with millisecond-scale 
temporal resolution and micrometer-scale spatial resolution. Multiple single-RBC functional 
parameters, including total hemoglobin concentration, oxygen saturation, flow speed, oxygen 
release rate, and metabolic rate of oxygen, can be quantified simultaneously in real time, which 
enables numerous biomedical studies and clinical applications. 
 
How to measure the effectiveness of therapy by measuring oxygenation of the target 
tissues  
Harold Swartz, Ph.D., Dartmouth University  
 
Because RBC transfusion typically aims to provide adequate oxygenation, evaluating the quality 
of RBC preparations should include direct demonstration of their effectiveness in improving 
target tissue oxygenation [32]. This should be done in both preclinical studies and human 
patients. Evaluating efficacy requires repeated direct measurements of oxygen in target tissues, 
the ability to measure continuously over clinically-relevant periods of time, and repeating these 
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measurements on multiple days. It is not sufficient to measure oxygen content in the circulation 
because it does not account for potential barriers to full equilibrium with cells in target tissues. 
Measurements in the circulation also do not account for the balance between oxygen delivery 
and consumption in target tissues. Therefore, it is desirable to make direct and repeated 
measurements of oxygen in target tissues to determine transfusion efficacy in each patient. 
 
Electron paramagnetic resonance (EPR) oximetry can make direct and repeated measurements 
of tissue oxygen in both preclinical models and human subjects [33]. This involves a one-time, 
minimally invasive, injection of appropriate paramagnetic materials into the target of interest. 
Subsequently, oxygen measurements can be made non-invasively as frequently as desired, 
including continuous and repetitive measurements at any desired time interval.  
 
Using EPR in vivo, oxygen was extensively and successfully measured in virtually all tissues in 
animals, ranging from mice to pigs. In the last 15 years, EPR studies in vivo were also extended 
to humans, with EPR dosimetry and oximetry measurements made at several institutions in the 
USA, Korea, Japan, and Belgium, confirming that EPR measurements in vivo can be made 
continuously and repeatedly. India Ink is an especially useful oxygen sensor, because it is 
minimally invasive (a simple needle stick, leaving a subcutaneous spot of India Ink similar to a 
tattoo) and the FDA determined that no special permission is needed for its use in human 
subjects. Therefore, this could be used clinically to monitor the effectiveness of an intervention 
to raise tissue pO2 initially, and then re-measure it whenever necessary. The apparatus required 
is simple and can be operated by minimally-trained individuals with a skill level similar to that for 
measuring blood pressure. EPR oximetry may also be used to determine when more widely 
available, but less intrinsically specific techniques (e.g., MRI or positron emission tomography), 
can provide the desired information regarding tissue oxygenation.  
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Clinical trial on tumor oxygenation using EPR oximetry with OxyChip 
Periannan Kuppusamy, Ph.D., Dartmouth Geisel School of Medicine 
 
We developed an EPR oximetry-based method to measure absolutes value of tissue oxygen 
(pO2) in clinical settings. It uses a paramagnetic oxygen sensor (OxyChip) containing LiNc-BuO 
microcrystals in a biocompatible polymer matrix [34]. In preclinical studies, OxyChip made direct 
and repeated pO2 measurements for a year or longer, without toxicity or changes in sensitivity. 
In clinical studies, OxyChip safely and effectively measured tumor pO2 in cancer patients 
undergoing surgery, radiation, or chemotherapy. To this end, following implantation into tumor 
tissue within 20 mm of the skin surface, pO2 measurements were performed noninvasively using 
an external radiofrequency coil at 1.2 GHz. Repeated pO2 measurements were made for 
weeks/months after OxyChip implantation, with values ranging from severely hypoxic (~1 
mmHg) to normal (>20 mmHg). Tumors had variable responses to 100% O2 via a non-
rebreathing face mask, with most showing a positive response to hyperoxyia intervention, 
whereas some showed no or negative responses. We also developed OxyChip as an adhesive 
film for noninvasive measurement of transcutaneous oxygen (TcpO2) levels, to evaluate blood 
perfusion in tissue immediately beneath the skin. These data are valuable in assessing wound 
healing, diagnosing peripheral vascular/arterial insufficiency, and predicting disease progression 
or response to therapy. In a cohort of healthy human subjects, repeated TcpO2 measurements 
were robust, reliable, and reproducible, with 7.8 ± 0.8 to 22.0 ± 1.0 mmHg in the volar forearm 
(N=29) and 8.1 ± 0.3 to 23.4 ± 1.3 mmHg in the foot (N=86). Thus, OxyChip can address a 
clinically-relevant need, enabling reliable and repeated pO2 measurements in tissues. This 
approach will support development and optimization of hypoxia modifiers to improve treatment 
outcomes. 
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Low field magnetic resonance imaging of tissue oxygen in vivo: Metabolic and 
physiologic imaging biomarkers of the tumor microenvironment to guide treatment in 
tumor bearing mice 
Murali Krishna Cherukuri, Ph.D., Radiation Biology Branch, National Cancer Institute, NIH 
 
The tumor microenvironment in solid tumors is characterized by regions of poor perfusion, 
hypoxia, and low pH. Biochemically, tumor cells, both in vitro and in vivo, display the aerobic 
glycolysis phenotype. Imaging techniques providing biomarkers reporting on these features 
would be useful in providing diagnostic/prognostic information and for developing appropriate 
treatments based on a priori information about the tumor microenvironment. 
Data describing the metabolic and physiologic microenvironments of three tumor xenografts in 
mice were shown using EPR imaging, to non-invasively provide quantitative pO2 maps, and 
metabolic MRI using hyperpolarized 13C-labeled pyruvate, to provide biochemical profiling [35]. 
These tumor-bearing mice were treated with radiation therapy or hypoxia-activated pro-drugs to 
evaluate the potential for the imaging biomarkers to predict treatment response. These data 
support the ability of these modalities to predict differences in the benefit of oxygen-dependent 
anti-tumor treatments in individual pancreatic tumor cell lines, which may help choose the best 
treatments for patients with pancreatic cancer. Three pre-clinical models using hyperpolarization 
MRI, with plans for clinical translation, were also presented: (1) glycolysis assessment as a 
biomarker for graft versus host disease; (2) in vivo pharmacodynamic assessment of a lactate 
dehydrogenase A inhibitor; and (3) monitoring the transition from low-grade glioma to 
glioblastoma in isocitrate dehydrogenase-1 mutant cells. 
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Conclusions 
In conclusion, the Symposium brought together a highly diverse group of participants to discuss 
multiple perspectives about tissue perfusion and oxygenation, a relatively understudied area 
that was identified as a research priority during the 2015 Transfusion Symposium [36]. The 
presentations and discussions highlighted important research needs and challenges, provided 
recommendations, and identified various opportunities; these are discussed in more detail 
below. 
 
Research Needs and Challenges 
The general consensus was that minimally-invasive or non-invasive methods to measure tissue 
oxygenation accurately are needed (1) pre-transfusion to predict who would benefit from RBC 
transfusions, and (2) post-transfusion to determine if the patient actually did benefit from this 
intervention. These methods are also required to enable testing the differential effects of various 
RBC products with specific characteristics (e.g., whole blood versus packed RBCs). The 
discussion built on a previous initiative to develop assessment tools to evaluate dynamic 
changes in microvascular blood flow and tissue oxygenation in clinical research applications.  
 
The presentations and panel discussions identified multiple promising biomarkers and 
assessment tools that could be applied clinically to assess tissue oxygenation pre- and post-
transfusion. These included: 
 NIRS as a non-invasive tool for continuously monitoring tissue oxygenation and 
hemodynamics, particularly in the brain. Nonetheless, rigorous testing in clinical studies 
is required to determine whether it can guide transfusion therapy to optimize care and 
improve outcomes. 
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 BOLD imaging to provide deep tissue visualization of oxygen delivery. However, it relies 
on measurements of hemoglobin saturation (rather than tissue oxygen content) and 
requires an MRI instrument. Nonetheless, it can provide reproducible, non-invasive 
estimation of tissue oxygenation in vascular tissues (e.g., kidney). 
 Multiple candidate molecules, including HIF, lactate-pyruvate, NAD/NADH, mitochondrial 
enzymes, and local CO2 production, that might provide biomarkers of local tissue 
oxygenation. Although HIF measurements are not yet clinically available to guide 
transfusion therapy, assessing the metabolic status of the tissue response to 
oxygenation may be an important complement to measuring oxygen itself.   
 PAM, a non-invasive, label-free method to image oxygen delivery from single flowing 
RBCs in vivo. It has millisecond-scale temporal resolution and micrometer-scale spatial 
resolution. Multiple single-RBC functional parameters can be quantified simultaneously 
in real time, suggesting its potential for clinically evaluating transfusion efficacy. 
 EPR oximetry for direct and repeated measurements of tissue oxygen. This involves a 
one-time, minimally invasive injection of appropriate paramagnetic materials into an area 
of interest. Subsequently, oxygen measurements can be made non-invasively and 
repetitively, including continuously. Therefore, it could repetitively monitor transfusion 
efficacy in raising tissue pO2 in clinically relevant settings.  
 Oxygen tension (pO2) imaging and sensing technologies to provide quantitative 
transcutaneous oxygenation measurements with potential applicability to sense 
transfusion-induced changes in tissue oxygenation. Ultrabright, "clickable" porphyrins, 
which can be functionalized for oxygen sensing applications, have now been used in 
clinical trials to measure transcutaneous pO2. 
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 Novel ultrasound tools, such as elastography, calcium contact, and microvascular 
assessment. These can be applied in early gestation for noninvasively evaluating human 
placenta, including local tissue oxygenation. 
 Phosphorescence quenching relies on the ability of non-bound, freely diffusing, 
dissolved oxygen in biological tissues to quench exogenous, phosphorescent, molecular 
probes. Because these measurements depend on phosphorescence decay time, as 
opposed to intensity, they are independent of local probe concentrations.  
 Biosensors of tissue-like hydrogel scaffolds can permanently reside subcutaneously and 
use existing mobile networks to provide real-time, continuous, wireless, biochemical data 
for remote viewing. Functionalized soft, porous oxygen sensing scaffolds with 
luminescent chemistries were active in vivo for years. The first such sensor is approved 
for use in the European Union and is awaiting FDA approval. 
 
Recommendations and Opportunities 
The following represent specific recommendations and research opportunities: 
 The ideal device would target deep tissues of interest (e.g., heart, brain, liver, gut, 
kidney), provide real-time bedside assessment of oxygen reserve (i.e., stress testing), 
and measure target tissue oxygen quantity and metabolic status .   
 Light-based reporter molecules that penetrate deeply are desirable because measuring 
oxygen levels just beneath the skin does not provide meaningful tissue oxygen status of 
vital organs. Although current MRI-based methods can overcome this limitation, they 
require an MRI scanner, making it less useful for transfusion decisions. Nonetheless, a 
miniaturized, bedside, MRI scanner could be valuable.  
 Transfusion efficacy would best be evaluated by simultaneously measuring SpO2, pCO2, 
pO2, bicarbonate, non-invasive oxygen consumption (VO2), carbon dioxide production 
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(VCO2), and lactate production; the availability of decision support tools to evaluate 
these data in an integrated way could enhance clinical decision making. 
 Although most existing methods determine oxygen concentration, other parameters, 
such as measuring acidosis via carbon dioxide and lactic acid, are important. Thus, non-
invasive methods that measure gas exchange (e.g., indirect calorimetry), could 
determine oxygen consumption efficacy and elimination of carbon dioxide. 
 New imaging detection methods, chemical sensors, photoacoustics, and metabolomic 
measurements of tissue oxygenation could be useful for assessing transfusion efficacy. 
 Physical methods (e.g., magnetic, photoacoustic, infrared) are generally non-invasive, 
but have limited signal penetration depth. Although PAM is promising, further study is 
required to test its applicability to humans.  
 Most non-invasive imaging methods detect tissue oxygenation by assessing hemoglobin 
saturation. Tools to measure tissue pO2 directly would be useful for providing spatial and 
temporal information regarding the effects of oxygen modifying agents. 
 Oxygen sensing probes that are accurate in low oxygen ranges would be useful. Most 
such probes have good sensitivity over 10 mmHg, but few are sensitive at 0.1-5 mmHg; 
the latter range of tissue hypoxia is where it is important to evaluate the effects of 
oxygenation agents. 
 Studies assessing tissue oxygenation responses to RBC transfusion would be 
strengthened by evaluating donor RBC characteristics, using information from the 
supplier (e.g., age, gender, storage duration, irradiation) and biomarker assessment of 
the unit itself (e.g., metabolomics).  
 Limited data exist regarding metabolic biomarkers that could improve on currently-
available blood tests (e.g., lactate), along with clinical features, to identify patients who 
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would benefit from RBC transfusion. Research areas could include metabolomic 
analysis of the hypoxic patient: 
o To identify serum- and/or RBC-based biomarkers to categorize patients better 
regarding who would, or would not, benefit from transfusion 
o To determine the extent to which these biomarkers (and the underlying 
physiology) can be corrected by transfusion, and to identify therapeutic 
requirements (e.g., when to transfuse, the transfusion goals, whether RBC 
quality affects whether transfusions correct underlying pathophysiology) 
 To evaluate transfusion efficacy, markers of short-term and long-term tissue well-being 
after transfusion are required. 
 Hemoglobin threshold-driven RBC transfusion practices in preterm infants currently do 
not incorporate measuring tissue oxygenation. Both donor and recipient factors should 
be considered to assess the effects of transfusion on tissue oxygenation. 
 Current NIRS methods do not integrate data on systemic arterial oxygen saturation or 
blood flow, limiting understanding of the underlying causes of changes in tissue oxygen 
saturation. 
 Study designs accounting for longitudinal measures across multiple RBC exposures 
could provide understanding of within-patient variation in transfusion responses that may 
relate to donor characteristics (e.g., RBC storage age, donor sex and age) or time-
varying recipient characteristics (e.g., anemia severity).  
 Multidisciplinary research programs, crossing multiple topical areas, could bring ideas 
together in a set of clinical studies where hypotheses and data could be addressed from 
various perspectives. Focusing on a specific patient population would narrow the scope 
and allow testing of specific ideas. Two important populations are models are neonates 
and patients with sickle-cell anemia. A consortium approach would enable testing 
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multiple hypotheses by pooling scientific and technological expertise and resources, 
including donor RBC quality in vitro, donor RBC quality post-transfusion (i.e., in vivo), 
and deep tissue oxygenation post-transfusion with correlation to peripheral oxygenation  
 Opportunities for smaller cross-disciplinary studies were also discussed, including 
evaluating multiple tools simultaneously to compare and contrast measurements of 
blood oxygen saturation and tissue perfusion post-transfusion.   
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